



LEUKEMIA & LYMPHOMA SOCIETY™


RESILIENCE THROUGH PROGRESS: SLOW GROWING NON-HODGKIN LYMPHOMA (NHL)

J.C. Villasboas B., MD
Assistant Professor of Medicine and Oncology
 Mayo Clinic College of Medicine and Science
Consultant, Division of Hematology
Director, Mayo Clinic Immune Monitoring Core Laboratory
 Mayo Clinic
 Rochester, MN

1

WELCOMING REMARKS

RESILIENCE THROUGH PROGRESS: SLOW GROWING NON-HODGKIN LYMPHOMA (NHL)



Lizette Figueroa-Rivera, MA
 Sr. Director, Education & Support
 The Leukemia & Lymphoma Society

LEUKEMIA & LYMPHOMA SOCIETY™

2

DISCLOSURES

RESILIENCE THROUGH PROGRESS: SLOW GROWING NON-HODGKIN LYMPHOMA (NHL)



Dr. J.C. Villasboas B.

Research Funding:

Aptose, CRISPR, Enterome, Epizyme, Genentech, Regeneron



3

Slow Growing (Indolent) Non-Hodgkin Lymphomas (iNHL)

J. C. Villasboas, MD

Assistant Professor of Medicine and Oncology, Mayo Clinic College of Medicine & Science

Consultant, Division of Hematology (Lymphoma | BMT | Cellular Therapy)

Director, Mayo Clinic Immune Monitoring Core Laboratory

Mayo Clinic, Rochester, MN

4

Conflicts of Interest

- Research Support
 - Aptose
 - CRISPR
 - Enterome
 - Epistemology
 - Genentech
 - Regeneron


5

Outline

- What are the iNHL?
- How common is iNHL?
- How do patients with FL present?
- What is the initial evaluation of a new FL patient?
- What is the prognosis of FL?
- How do I treat FL?
- What is histological transformation?


6

What are the iNHL?



7

What are the iNHL?



8

How common is NHL?



Source: United States Cancer Statistics (www.cdc.gov/cancer/uscs/)

9


How common is NHL?



- ~ 4% of all cases of cancer diagnosed in U.S. per year
- ~70,000 new cases in the U.S. per year
- More than 80 subtypes


10

How common is iNHL?



11


How common is iNHL?



• ~ 40% of all NHL cases diagnosed in U.S. per year

12


How common is iNHL?



- iNHL subtypes include
 - Marginal zone lymphoma (MZL)
 - Small lymphocytic lymphoma (SLL)
 - Lymphoplasmacytic lymphoma
 - Primary cutaneous follicle center lymphoma
 - Follicular lymphoma (FL)

13


How common is iNHL?



- Follicular lymphoma (FL) is the iNHL prototype
 - Indolent (low grade) B-NHL
 - ~ 35% of all NHL cases in U.S.
 - 65y is median age at diagnosis
 - Rare pediatric and adolescent subtypes

14


How do patients with FL present?



- Enlarged peripheral lymph nodes
- Enlarged internal lymph nodes
- Enlarged spleen
- Abnormal blood counts

15


How do patients with FL present?



- Enlarged peripheral lymph nodes
- Enlarged internal lymph nodes
- Enlarged spleen
- Abnormal blood counts

16


How do patients with FL present?



- Enlarged peripheral lymph nodes
- Enlarged internal lymph nodes
- Enlarged spleen
- Abnormal blood counts

17


How do patients with FL present?



- Enlarged peripheral lymph nodes
- Enlarged internal lymph nodes
- Enlarged spleen
- Abnormal blood counts

18

How do patients with FL present?



- Enlarged peripheral lymph nodes
- Enlarged internal lymph nodes
- Enlarged spleen
- Abnormal blood counts


19

Outline

- What are the iNHL?
- How common is iNHL?
- How do patients with FL present?
- What is the initial evaluation of a new FL patient?
- What is the prognosis of FL?
- How do I treat FL?
- What is histological transformation?

20


What is the initial evaluation of a new FL patient?



- Blood tests
- Bone marrow biopsy
- PET-CT scan

21

What is the initial evaluation of a new FL patient?



22

What is the prognosis of FL?

Follicular Lymphoma International Prognostic Index (FLIPI) ☆


Estimates overall survival based on clinical information.

When to Use ▾ Pearls/Pitfalls ▾ Why Use ▾

Age > 60 years	No 0	Yes +1
>4 nodal sites <small>See Evidence for nodal diagram.</small>	No 0	Yes +1
LDH elevated	No 0	Yes +1
Hemoglobin <120 g/L or 12 g/dL	No 0	Yes +1
Stage III-IV	No 0	Yes +1

23

What is the prognosis of FL?



24

What is the prognosis of FL?

FLIPI CAN

- Be easily calculated using readily available clinical variables
- Estimate chance of survival at 5y from diagnosis

FLIPI CANNOT

25

What is the prognosis of FL?

FLIPI CAN

- Be easily calculated using readily available clinical variables
- Estimate chance of survival at 5y from diagnosis

FLIPI CANNOT

- Tell if/when you need to start treatment
- Estimate the chance of successful treatment
- Estimate chance of survival in patients with relapsed FL

26

How do I treat FL?

Watchful Waiting

Radiation Therapy

Immunotherapy

Chemotherapy

Targeted therapy

Immune modulators

27

How do I treat FL?



Watchful Waiting

Radiation Therapy

Immunotherapy

Chemotherapy

Targeted therapy

Immune modulators

+8y



28

How do I treat FL?



78yo M

- Watchful Waiting
- Radiation Therapy
- Immunotherapy
- Chemotherapy
- Targeted therapy
- Immune modulators

+9y
Watchful Waiting



29


How do I treat FL?



78yo M


- Watchful Waiting
- Radiation Therapy
- Immunotherapy
- Chemotherapy
- Targeted therapy
- Immune modulators

+3y




30

How do I treat FL?




60yo M

- Watchful Waiting
- Radiation Therapy
- Immunotherapy
- Chemotherapy
- Targeted therapy
- Immune modulators



HT



Overall Survival (years)

~2% risk per year

J Clin Oncol 26:5165-5169 © 2008

31

How do I treat FL?

- Watchful Waiting
- Radiation Therapy
- Immunotherapy
- Chemotherapy
- Targeted therapy
- Immune modulators

A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma

Location: [Interventional](#) [Show What is this?](#)

Study phase: [1/2](#) [Show What is this?](#)

About this study

The purpose of this study is to define the recommended dose, safety, tolerability, immunogenicity, and preliminary effectiveness of EO2463 during monotherapy and in combination with lenalidomide and/or rituximab in patients with indolent Non-Hodgkin's Lymphoma (NHL).

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location	Status	Contact
Rochester, Minn.	✓ Open for enrollment	View complete study & contact information

Clinical Trials

32

Outline

- What are the iNHL?
- How common is iNHL?
- How do patients with FL present?
- What is the initial evaluation of a new FL patient?
- What is the prognosis of FL?
- How do I treat FL?
- What is histological transformation?

33

Thank you



34

ASK A QUESTION

RESILIENCE THROUGH PROGRESS: SLOW GROWING NON-HODGKIN LYMPHOMA (NHL)

Ask a question by **phone**:

Press star (*) then the number 1 on your keypad.

Ask a question by **web**:

Click "Ask a question"

Type your question

Click "Submit"

Due to time constraints, we can only take one question per person. Once you've asked your question, the operator will transfer you back into the audience line.



35

LLS EDUCATION & SUPPORT RESOURCES



HOW TO CONTACT US:

To contact an **Information Specialist** about disease, treatment and support information, resources and clinical trials:

Call: **(800) 955-4572**
Monday to Friday, 9 a.m. to 9 p.m. ET

Chat live online: www.LLS.org/InformationSpecialists
Monday to Friday, 10 a.m. to 7 p.m. ET

Email: www.LLS.org/ContactUs
All email messages are answered within one business day.

CLINICAL TRIAL SUPPORT CENTER

Work one-on-one with an LLS Clinical Trial Nurse Navigator who will help you find clinical trials and personally assist you throughout the entire clinical-trial process.

www.LLS.org/Navigation



NUTRITION CONSULTATIONS
Our registered dietitian has expertise in oncology nutrition and provides free one-on-one consultations by phone or email.
www.LLSNutrition.org



36

LLS EDUCATION & SUPPORT RESOURCES




Online Chats

Online Chats are free, live sessions, moderated by oncology social workers. To register for one of the chats below, or for more information, please visit www.LLS.org/Chat



Education Videos

View our free education videos on disease, treatment, and survivorship. To view all patient videos, please visit www.LLS.org/EducationVideos



Patient Podcast

The Bloodline with LLS is here to remind you that after a diagnosis comes hope. To listen to an episode, please visit www.TheBloodline.org



37

LLS EDUCATION & SUPPORT RESOURCES

877.557.2672

LEUKEMIA & LYMPHOMA SOCIETY

Help With Finances

The Leukemia & Lymphoma Society (LLS) offers financial assistance* to help individuals with blood cancer.

The LLS Patient Aid Program provides financial assistance to blood cancer patients in active treatment. Eligible patients will receive a \$100 stipend. Visit www.LLS.org/PatientAid


The Urgent Need Program, established in partnership with Maggie's Love, helps pediatric and young adult blood cancer patients, or adult blood cancer patients who are enrolled in clinical trials, with acute financial need. The program provides a \$500 grant to assist with non-medical expenses, including utilities, rent, mortgage, food, lodging, dental care, child care, elder care, and other essential needs. Visit www.LLS.org/UrgentNeed

The Susan Long Pay-It-Forward Patient Travel Assistance Program provides blood cancer patients a \$500 grant to assist with transportation and lodging related expenses. Visit www.LLS.org/Travel

The Co-Pay Assistance Program offers financial support toward the cost of insurance co-payments and/or insurance premiums for prescription drugs. Visit www.LLS.org/CoPay

*Funding for LLS Co-pay Assistance Program is provided by pharmaceutical companies. Funding for other LLS financial assistance programs is provided by donations from individual donors, companies, and LLS employees.

The Leukemia & Lymphoma Society (LLS) offers the following financial assistance programs to help individuals with blood cancers: www.LLS.org/Finances



To order free materials: www.LLS.org/Booklets



38



THANK YOU

Please complete a short survey to provide us with your valuable feedback and to be entered to win a gift card: www.LLSeval.org

We have one goal: A world without blood cancers



LEUKEMIA &
LYMPHOMA
SOCIETY